⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Home/Drugs/Pamrevlumab

Pamrevlumab

pamrevlumab

Phase 3

Sponsor: FibroGen

Indication: IPF / Pancreatic Cancer

Mechanism of Action

Connective Tissue Growth Factor (CTGF) inhibitor

Target: CTGF

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

TERMINATEDNCT04419558

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase:PHASE3Org:Kyntra Bio

COMPLETED

Relevant Publications (PubMed)

Network meta-analysis of pharmacological treatments for idiopathic pulmonary fibrosis: evaluating effects on lung function.

Yin Y, Wu X, Liu Z et al.

Front Pharmacol2026

Caregiver burden in Duchenne muscular dystrophy in Europe, Japan, and the United States - a real-world study.

Strober J, Ishigaki K, Posner N et al.

BMC Neurol2026 Jan 10

Breaking new ground in heart failure management: novel therapies and future frontiers.

Khalid A, Rodriguez P, Tasouli-Drakou V et al.

Front Cardiovasc Med2025

New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review.

Validated Models

This drug has been validated in the following preclinical models:

NCT00102297

Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus

Phase:PHASE1Org:Kyntra Bio

COMPLETEDNCT02210559

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Phase:PHASE1, PHASE2Org:Kyntra Bio

COMPLETEDNCT05262309

An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19

Phase:PHASE2, PHASE3Org:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

WITHDRAWNNCT02851381

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Phase:NAOrg:Jonsson Comprehensive Cancer Center

View all trials on ClinicalTrials.gov

Sassetti C, Borrelli C, Mazuy M et al.

Pharmaceuticals (Basel)2025 Apr 28

Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab.

Kim GH, Zhang X, Brown MS et al.

BMJ Open2025 May 12

View more on PubMed